Diabetes Care Devices Market Worth $4.3 billion by 2025 | Significant advancements and leveraging of artificial intelligence and big data

By -

China to hold the largest share in the market in 2020, followed by India

(EMAILWIRE.COM, July 24, 2020 ) The research study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

How the Market Growth looks like and Industry Segmentation?

The Global Diabetes Care Devices Market size is projected to reach USD 4.3 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 16.2% during the forecast period.

Based on type, the diabetes care devices (BRIC) market has been segmented into blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. Under the blood glucose monitoring systems segment, the test strips segment is estimated to account for the largest share in 2020. The dominance of this segment can be attributed to the frequent requirement of test strips in blood glucose monitoring systems.

Based on end user, the diabetes care devices (BRIC) market has been segmented into hospitals & specialty clinics and self/home healthcare. The self/home healthcare segment is estimated to hold the largest share in 2020. This segment is also projected to grow at the highest CAGR during the forecast period. The rapid growth of the segment is attributed to the increasing awareness of diabetes self-monitoring and management, increasing recommendations from physicians for home healthcare for diabetes, and the increasing utility of home-based diabetes care devices to provide real-time insights regarding the condition due to the technological advancements of these systems.

Browse 64 market data Tables and 42 Figures spread through 168 Pages and in-depth TOC - Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=375

Major Market Growth Drivers:
- Sharp increase in diabetes in the past decade
- Favorable national health strategies
- Government-LED endorsement of the medical device industry
- Significant advancements and leveraging of artificial intelligence and big data

Recent Developments:

- In February 2020, Abbott (US) received US FDA approval for the use of FreeStyle Libre 14-day Flash glucose monitoring systems in hospitals.

- In February 2020, Insulet signed a commercialization agreement with DexCom, Inc. (US) to allow its current and future CGM systems to connect to the former’s tubeless insulin pump system, OMNIPOD Horizon system.

- In April 2020, Ypsomed (Switzerland) entered into a partnership with DexCom, Inc. (US) to integrate its mylife YpsoPump data with DexCom’s G6 CGM sensors to form a hybrid closed-loop system.

- In January 2020, LifeScan (US) entered into a partnership agreement with DKSH to provide marketing, sales, regulatory services, as well as distribution and logistics for the sales of LifeScan products in the Philippines, Vietnam, Malaysia, Indonesia, Thailand, Hong Kong, and Taiwan.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=375

Geographical Regions Mapped in Report:

China is projected to hold the largest share in the diabetes medical devices market during the forecast period. This can be attributed to the sharp increase in diabetes in the country, favorable national health strategies, and government-led endorsements of medical device companies.

Major Key Players Mapped in Research Report:

The prominent players in the gcc diabetes care devices market include Medtronic plc (Ireland), B. Braun (Germany), DexCom, Inc. (US), Abbott (US), F. Hoffman-La Roche Ltd. (Switzerland), Ascensia Diabetes Care Holdings AS (Switzerland), LifeScan (US), AgaMatrix Holdings LLC (US), Acon Laboratories, Inc. (US), ARKRAY USA, Inc. (US), Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Sanofi (France), Terumo Corporation (Japan), SD Biosensor, Inc. (South Korea), MicroGene Diagnostic Systems Pvt. Ltd. (India), Ypsomed Holdings AG (Switzerland), Dr. Morepen (India), Sinocare, Inc. (China), Bionime Corporation (Taiwan), and Rossmax International Ltd. (Taiwan).

Media Contact

Read other news from MarketsandMarkets™

Timing Devices Market Size, Share, Revenue Trends & Forecast to 2030

MarketsandMarkets™ - Sep 18, 2023
Timing Devices Market by Type (Oscillators, Atomic Clocks, Clock Generators, Clock Buffers, Jitter Attenuators), Material (Crystal, Silicon, Ceramic), Vertical (Consumer Electronics, Automotive) and Region - Global Forecast to 2030 ...Read more

Artificial Intelligence Market Segmented by Product, Top Manufacturers, Geography Trends & Growth Opportunity to 2030

MarketsandMarkets™ - Sep 18, 2023
Artificial Intelligence technology such as machine learning, natural language processing, computer vision, and others are revolutionizing various sectors, including healthcare, finance, manufacturing, and retail. ...Read more

Digital PCR (dPCR) and Real-time PCR (qPCR) Market worth $12.4 billion by 2028, at a CAGR of 7.8%.

MarketsandMarkets™ - Sep 18, 2023
"Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospital, Diagnostic Labs, Pharma, Biotech, CROs) - Global Forecast to 2028". ...Read more